BioCatalystWatch
OPKWorkspace / OPK / OverviewCompany library
Price
Market cap
Next catalystExpected 1H 2027MDX2001 — advanced solid tumors · Phase 1 dataCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

MDX2301

SARS-CoV-2 spike RBD

PreINDP1P2P3FilingApproved
Upcoming / outlook

MDX2001

c-Met × Trop2 × CD3 × CD28

PreINDP1P2P3FilingApproved
Upcoming / outlook

OPK88006

GLP-1 receptor × Glucagon receptor

PreINDP1P2P3FilingApproved
MDX2004

CD3 × CD28 × 4-1BB (CD137)

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

MDX2001

c-Met × Trop2 × CD3 × CD28

PreINDP1P2P3FilingApproved
Upcoming / outlook

MDX2004

CD3 × CD28 × 4-1BB (CD137)

PreINDP1P2P3FilingApproved
Upcoming / outlook

MDX2301

SARS-CoV-2 spike RBD

PreINDP1P2P3FilingApproved
Upcoming / outlook

OPK88006

GLP-1 receptor × Glucagon receptor

PreINDP1P2P3FilingApproved

Other pipelines

Growth hormone receptor (GHR)

PreINDP1P2P3FilingApproved
OXM

GLP-1 receptor × Glucagon receptor

PreINDP1P2P3FilingApproved
OPK88006

GLP-1 receptor × Glucagon receptor

PreINDP1P2P3FilingApproved
OPK88006

GLP-1 receptor × Glucagon receptor

PreINDP1P2P3FilingApproved

GLP-1 receptor × Glucagon receptor

PreINDP1P2P3FilingApproved
EB612

PreINDP1P2P3FilingApproved
EB618

GLP-1 receptor × Glucagon receptor

PreINDP1P2P3FilingApproved
oral OXM

GLP-1 receptor × Glucagon receptor

PreINDP1P2P3FilingApproved
MDX2003

CD19 × CD20 × CD3 × CD28

PreINDP1P2P3FilingApproved
RAYALDEE®

PreINDP1P2P3FilingApproved

Partner / License out

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

EBV gH × EBV gL × EBV gp42 × EBV gp350

PreINDP1P2P3FilingApproved

Approved / commercial

RAYALDEE®

Approved

PreINDP1P2P3FilingApproved
Upcoming / outlook

History / paused

PreINDP1P2P3FilingApproved

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

OPK SEC archive